Previous 10 | Next 10 |
- Multi-Cancer Assay Highly Sensitive and Specific in Screening for Detection of Early-Stage Cancers, Able to Identify Tumor Tissue of Origin with High Accuracy Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new data demonstrating the a...
April showers came early for biotech investors, leaving the SPDR S&P Biotech ETF (NYSEMKT: XBI) down over 17% year to date, trailing the S&P 500 . The good news is that solid companies are on sale. 10x Genomics (NASDAQ: TXG) and Guardant Health (NASDAQ: GH)...
NeoGenomics (NASDAQ:NEO) jumped 22% on speculation that the operator of cancer testing labs could become an activist target. NeoGenomics (NEO) shares have dropped "significantly" in recent months and the company had an "abrupt" management change and some "value-destructive" acquisitions,...
Shares of Guardant Health Inc. (NASDAQ:GH) traded at a new 52-week high today of $184.10. This new high was reached on above average trading volume as 43.2 million shares traded hands, while the average 30-day volume is approximately 1.1 million shares. There is potential upside of 4.2% ...
Guardant Health (NASDAQ:GH) is collaborating with health record company Epic to integrate its broad portfolio of cancer tests with Epic. The company said the integration will make it easier for health systems, community healthcare providers and retail health clinics to make Guardant bloo...
Partnership will Make Guardant Health Cancer Tests Available to Over 250 Million Patients with a Record in Epic Integration Will Simplify the Process for Clinicians to Order Tests and Access Results Directly in the Patient Record Guardant Health, Inc. (Nasdaq: GH), a lea...
Shares of precision oncology company Guardant Health (NASDAQ: GH) popped 9.8% higher today as of market close. There was little in the way of news from Guardant Health that caused the spike, but there was general strength across the biotech space while the stock market overall was f...
Philippe Laffont’s 13F portfolio value decreased from $24.58B to $22.55B this quarter. They increased Tesla and Microsoft while reducing Moderna, Snowflake, DoorDash, Marqeta, and Twilio. They also added Pfizer, Visa, and Applied Materials while dropping UiPath. For f...
Halvorsen's 13F portfolio value decreased from $36.04B to $34.49B this quarter. The number of positions increased from 96 to 107. Viking Global added Twilio, Workday, and Aon plc while dropping Fidelity National Information Services and Snowflake. The top three positions are Ginkg...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Guardant360 ® CDx, a liquid biopsy test for tumor mutation profiling, also known as compr...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
6.02%Change Percent:
Guardant Health Inc. Company Name:
GH Stock Symbol:
NASDAQ Market:
Guardant Health Inc. Website:
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...